Profile data is unavailable for this security.
About the company
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
- Revenue in USD (TTM)0.00
- Net income in USD-5.30m
- Incorporated2020
- Employees4.00
- LocationVirios Therapeutics Inc44 Milton AvenueALPHARETTA 30009United StatesUSA
- Websitehttps://www.virios.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ProtoKinetix, Inc. | 0.00 | -369.97k | 4.91m | 0.00 | -- | 12.10 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Clearmind Medicine Inc | 0.00 | -8.44m | 4.91m | -- | -- | 1.39 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
Cingulate Inc | 0.00 | -19.10m | 4.94m | 13.00 | -- | 1.32 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
Biostax Corp | 0.00 | -1.51m | 5.02m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Windtree Therapeutics Inc | 0.00 | -11.38m | 5.04m | 15.00 | -- | 0.5303 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
Weed Inc | 0.00 | 57.30k | 5.31m | 2.00 | 84.31 | 706.08 | 61.40 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Burzynski Research Institute Inc | 0.00 | -1.42m | 5.40m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
Virios Therapeutics Inc | 0.00 | -5.30m | 5.53m | 4.00 | -- | 1.76 | -- | -- | -0.2603 | -0.2603 | 0.00 | 0.113 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
ELEVAI Labs Inc | 2.47m | -4.75m | 5.65m | 18.00 | -- | 2.00 | -- | 2.29 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
Marizyme Inc | 364.96k | -52.51m | 5.65m | 11.00 | -- | -- | -- | 15.49 | -0.974 | -0.974 | 0.004 | -0.0712 | 0.0125 | 1.31 | 10.00 | 33,178.18 | -179.49 | -59.02 | -742.64 | -64.47 | 70.17 | 70.38 | -14,389.19 | -9,435.92 | 0.038 | -0.6989 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 6.02m | 3.00 | -- | 0.4203 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
Transcode Therapeutics Inc | 0.00 | -17.91m | 6.06m | 10.00 | -- | 1.93 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 6.11m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Xenetic Biosciences Inc | 2.52m | -4.70m | 6.12m | 4.00 | -- | 0.8219 | -- | 2.43 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 208.88k | 0.75% |
Geode Capital Management LLCas of 30 Jun 2024 | 174.47k | 0.63% |
UBS Securities LLCas of 30 Jun 2024 | 151.78k | 0.55% |
G1 Execution Services LLCas of 30 Jun 2024 | 65.99k | 0.24% |
HRT Financial LLCas of 30 Jun 2024 | 57.54k | 0.21% |
McCollum Christoferson Group LLCas of 30 Jun 2024 | 57.00k | 0.21% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 52.83k | 0.19% |
XTX Markets LLCas of 30 Jun 2024 | 42.65k | 0.15% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 30.00k | 0.11% |
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 24.04k | 0.09% |